Chartwell Investment Partners LLC Purchases 11,362 Shares of Natera, Inc. (NASDAQ:NTRA)

Chartwell Investment Partners LLC raised its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 37.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,302 shares of the medical research company's stock after purchasing an additional 11,362 shares during the period. Chartwell Investment Partners LLC's holdings in Natera were worth $5,243,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Natera by 19.2% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company's stock valued at $827,000 after buying an additional 1,457 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in shares of Natera by 28.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 17,586 shares of the medical research company's stock valued at $1,608,000 after purchasing an additional 3,927 shares in the last quarter. Swiss National Bank grew its holdings in Natera by 1.5% in the first quarter. Swiss National Bank now owns 225,400 shares of the medical research company's stock worth $20,615,000 after purchasing an additional 3,300 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Natera by 4.7% during the first quarter. Sei Investments Co. now owns 368,942 shares of the medical research company's stock valued at $33,744,000 after buying an additional 16,712 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock worth $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53. Following the transaction, the chief executive officer now owns 200,710 shares of the company's stock, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Natera news, insider Jonathan Sheena sold 12,000 shares of the business's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now owns 287,441 shares in the company, valued at approximately $34,783,235.41. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,583 shares of the company's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the sale, the chief executive officer now owns 200,710 shares of the company's stock, valued at approximately $23,866,426.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,464 shares of company stock valued at $5,849,977. 7.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Stephens restated an "overweight" rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. TD Cowen increased their price objective on Natera from $137.00 to $145.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Canaccord Genuity Group raised their target price on shares of Natera from $145.00 to $150.00 and gave the company a "buy" rating in a research note on Tuesday, October 29th. Finally, Sanford C. Bernstein increased their price target on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus target price of $125.69.

Natera Stock Performance

NASDAQ NTRA traded up $1.15 on Tuesday, reaching $135.12. 2,439,300 shares of the stock were exchanged, compared to its average volume of 1,313,506. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company's 50-day simple moving average is $124.66 and its two-hundred day simple moving average is $114.21. Natera, Inc. has a one year low of $46.96 and a one year high of $140.00. The firm has a market capitalization of $16.71 billion, a PE ratio of -54.68 and a beta of 1.53.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.